Patents by Inventor Sarah Greenlee

Sarah Greenlee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Selective Reduction of Allelic Variants
    Publication number: 20220403386
    Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate diseases, including neurodegenerative diseases, such as Huntington's Disease (HD).
    Type: Application
    Filed: January 18, 2022
    Publication date: December 22, 2022
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Sarah Greenlee, Eric E. Swayze
  • Selective Reduction of Allelic Variants
    Publication number: 20200377946
    Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a huntingtin gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate Huntington's Disease (HD).
    Type: Application
    Filed: January 14, 2020
    Publication date: December 3, 2020
    Applicants: Ionis Pharmaceuticals, Inc., The University of British Columbia
    Inventors: C. Frank Bennett, Michael Hayden, Susan M. Freier, Sarah Greenlee, Jeffrey Carroll, Simon Warby, Eric E. Swayze
  • Compounds and methods for detecting oligonucleotides
    Patent number: 10752940
    Abstract: The present invention provides methods of detecting and/or quantitating a target oligonucleotide in a biological sample.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: August 25, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Sarah Greenlee, Zhengrong Yu, Thazha P. Prakash, John E. Matson
  • SELECTIVE REDUCTION OF ALLELIC VARIANTS
    Publication number: 20190002877
    Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate diseases, including neurodegenerative diseases, such as Huntington's Disease (HD).
    Type: Application
    Filed: April 24, 2018
    Publication date: January 3, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Sarah Greenlee, Eric E. Swayze
  • SELECTIVE REDUCTION OF ALLELIC VARIANTS
    Publication number: 20180291453
    Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a huntingtin gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate Huntington's Disease (HD).
    Type: Application
    Filed: December 18, 2017
    Publication date: October 11, 2018
    Applicants: Ionis Pharmaceuticals, Inc., The University of British Columbia
    Inventors: C. Frank Bennett, Michael Hayden, Susan M. Freier, Sarah Greenlee, Jeffrey Carroll, Simon Warby, Eric E. Swayze
  • COMPOUNDS AND METHODS FOR DETECTING OLIGONUCLEOTIDES
    Publication number: 20160281148
    Abstract: The present invention provides methods of detecting and/or quantitating a target oligonucleotide in a biological sample.
    Type: Application
    Filed: November 10, 2014
    Publication date: September 29, 2016
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Sarah Greenlee, Zhengrong Yu, Thazha P. Prakash, John E. Matson
  • SELECTIVE REDUCTION OF ALLELIC VARIANTS
    Publication number: 20150329859
    Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate diseases, including neurodegenerative diseases, such as Huntington's Disease (HD).
    Type: Application
    Filed: December 23, 2014
    Publication date: November 19, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: C. Frank Bennett, Susan M. Freier, Sarah Greenlee, Eric E. Swayze
  • SELECTIVE REDUCTION OF ALLELIC VARIANTS
    Publication number: 20150292015
    Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a huntingtin gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate Huntington's Disease (HD).
    Type: Application
    Filed: March 3, 2015
    Publication date: October 15, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: C. Frank Bennett, Michael Hayden, Susan M. Freier, Sarah Greenlee, Jeffrey Carroll, Simon Warby, Eric E. Swayze
  • Selective reduction of allelic variants
    Patent number: 9006198
    Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a huntingtin gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate Huntington's Disease (HD).
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: April 14, 2015
    Assignees: Isis Pharmaceuticals, Inc., The University of British Columbia
    Inventors: C. Frank Bennett, Michael Hayden, Susan M. Freier, Sarah Greenlee, Jeffrey Carroll, Simon Warby, Eric E. Swayze
  • Selective reduction of allelic variants
    Patent number: 8957040
    Abstract: Disclosed herein are antisense compounds and methods for selectively of reducing expression of an allelic variant of a gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate diseases, including neurodegenerative, such as Huntington's Disease (HD).
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: February 17, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Sarah Greenlee, Eric E. Swayze
  • SELECTIVE REDUCTION OF ALLELIC VARIANTS
    Publication number: 20130046007
    Abstract: Disclosed herein are antisense compounds and methods for selectively of reducing expression of an allelic variant of a gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate diseases, including neurodegenerative, such as Huntington's Disease (HD).
    Type: Application
    Filed: February 8, 2011
    Publication date: February 21, 2013
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Sarah Greenlee, Eric E. Swayze
  • SELECTIVE REDUCTION OF ALLELIC VARIANTS
    Publication number: 20130046008
    Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a huntingtin gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate Huntington's Disease (HD).
    Type: Application
    Filed: February 8, 2011
    Publication date: February 21, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Michael Hayden, Susan M. Freier, Sarah Greenlee, Jeffrey Carroll, Simon Warby, Eric E. Swayze